Skip to Main Content

Advertisement

Skip Nav Destination

Issues

In This Issue

In the Spotlight

In Focus

Review

Research Brief

Quantification of the precision oncology landscape and clinical actionability in patients with cancer shows an increase in the fraction of genomic biomarkers of response to an approved precision oncology therapy.

Research Articles

Nemtabrutinib, a reversible inhibitor of both wild-type and C481-mutated BTK, demonstrates safety and preliminary efficacy in patients with relapsed or refractory B cell malignancies.

Xaluritamig, a novel STEAP1 × CD3 XmAb 2+1 immune therapy for metastatic castrationresistant prostate cancer, can be safely administered and shows encouraging antitumor activity, which supports further development.

Characterization of AMG 509 (xaluritamig) in preclinical models demonstrated its potent antitumor activity against STEAP1-expressing prostate tumor cells and supported its advancement as the first STEAP1-targeted T-cell engager in clinical development.

A multi-modal liquid biopsy assay can detect cancer in patients with Li-Fraumeni syndrome (LFS) earlier than current clinical surveillance methods, suggesting that implementation of this method could improve care for patients with LFS.

Ablation of the histone methyltransferase SUV39H1 enhances 41BB-based chimeric antigen receptor T cell long-term function by increasing stemness differentiation and in vivo persistence which protects against solid tumor relapses and rechallenges.

Genetic disruption of SUV39H1 enhances the expansion, long-term function, and antitumor efficacy of human CAR T cells in both leukemia and prostate tumor models, suggesting that this strategy could improve adoptive cell therapies in cancer.

While many nucleotides contribute structurally to DNA, GTP was found to regulate DNA repair and genotoxic treatment responses in preclinical models through a signaling mechanism involving the G protein Rac1, protein phosphatase 5, and Abl-interactor 1.

Pancreatic cancer cells deplete vitamin B6 (VB6) in the tumor microenvironment, and supplementation of VB6 or use of agents that block VB6-dependent one-carbon metabolism amplify natural killer cell antitumor immunity and inhibit tumor growth in pancreatic cancer models.

News in Brief

News in Depth

Research Watch

Clinical Trials
Clonal Hematopoiesis
Genetic Ancestry
Metabolism
Glioma
Immunology
Antibodies
Synthetic Lethality
Breast Cancer
Genomics
Leukemia
Immunology
Drug Combinations
Tumor Initiation

Acknowledgment to Reviewers

Close Modal

or Create an Account

Close Modal
Close Modal